MaxCyte Valuation
| MXCT Stock | USD 3.52 0.14 4.14% |
At this time, the firm appears to be undervalued. MaxCyte secures a last-minute Real Value of $5.14 per share. The latest price of the firm is $3.52. Our model forecasts the value of MaxCyte from analyzing the firm fundamentals such as Return On Equity of -0.16, profit margin of (0.78) %, and Current Valuation of 233.16 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting MaxCyte's valuation include:
Price Book 1.7407 | Enterprise Value 233.2 M | Enterprise Value Ebitda (11.07) | Price Sales 8.1427 | Enterprise Value Revenue 5.1133 |
Undervalued
Today
Please note that MaxCyte's price fluctuation is slightly risky at this time. Calculation of the real value of MaxCyte is based on 3 months time horizon. Increasing MaxCyte's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
MaxCyte's intrinsic value may or may not be the same as its current market price of 3.52, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.52 | Real 5.14 | Target 10.0 | Hype 3.51 |
The intrinsic value of MaxCyte's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence MaxCyte's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of MaxCyte helps investors to forecast how MaxCyte stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of MaxCyte more accurately as focusing exclusively on MaxCyte's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use MaxCyte's intrinsic value based on its ongoing forecasts of MaxCyte's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against MaxCyte's closest peers.
MaxCyte Cash |
|
MaxCyte Valuation Trend
MaxCyte's real value is important for investors to make better decisions and a more accurate overall view of MaxCyte's financial worth over time. Using both MaxCyte's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
MaxCyte Revenue by Product
MaxCyte Total Value Analysis
MaxCyte is now forecasted to have valuation of 233.16 M with market capitalization of 371.3 M, debt of 18.74 M, and cash on hands of 240.89 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the MaxCyte fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
233.16 M | 371.3 M | 18.74 M | 240.89 M |
MaxCyte Investor Information
About 71.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.74. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MaxCyte recorded a loss per share of 0.34. The entity had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from MaxCyte's historical financial statements, MaxCyte is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.MaxCyte Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. MaxCyte has an asset utilization ratio of 15.39 percent. This implies that the Company is making $0.15 for each dollar of assets. An increasing asset utilization means that MaxCyte is more efficient with each dollar of assets it utilizes for everyday operations.MaxCyte Ownership Allocation
The majority of MaxCyte outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in MaxCyte to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in MaxCyte. Please pay attention to any change in the institutional holdings of MaxCyte as this could imply that something significant has changed or is about to change at the company.MaxCyte Profitability Analysis
The company reported the previous year's revenue of 41.29 M. Net Loss for the year was (37.92 M) with profit before overhead, payroll, taxes, and interest of 39.16 M.About MaxCyte Valuation
The stock valuation mechanism determines MaxCyte's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of MaxCyte based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of MaxCyte. We calculate exposure to MaxCyte's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of MaxCyte's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 36.5 M | 19.4 M | |
| Pretax Profit Margin | (0.92) | (0.96) | |
| Operating Profit Margin | (1.17) | (1.11) | |
| Net Loss | (0.92) | (0.96) | |
| Gross Profit Margin | 0.89 | 0.70 |
MaxCyte Growth Indicators
Investing in growth stocks can be very risky. If the company such as MaxCyte does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 103.3 M |
MaxCyte Current Valuation Indicators
MaxCyte's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final MaxCyte's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as MaxCyte, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use MaxCyte's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes MaxCyte's worth.Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.